Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases
Del Pozo, Victoria (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Bobolea, Irina (Hospital Clínic i Provincial de Barcelona)
Rial, Manuel J. (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias)
Espigol Frigolé, Georgina (Hospital Clínic i Provincial de Barcelona)
Solans, Roser (Hospital Universitari Vall d'Hebron)
Hernández Rivas, Jesús María (Hospital Universitario de Salamanca)
Mora, Elvira (Hospital Universitari i Politècnic La Fe (València))
Crespo Lessmann, Astrid (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Izquierdo Alonso, José Luis (Hospital Universitario de Guadalajara)
Domínguez Sosa, María Sandra (Hospital Universitario de Gran Canaria Dr. Negrín)
Maza Solano, Juan (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Atienza-Mateo, Belén (Instituto de Investigación Marqués de Valdecilla)
Bañas Conejero, David (Hospital Universitario de Gran Canaria Dr. Negrín)
Moure, Abraham L. (Hospital Universitario de Gran Canaria Dr. Negrín)
Rua Figueroa, Íñigo (Hospital Universitario de Gran Canaria Dr. Negrín)
Universitat Autònoma de Barcelona. Departament de Medicina

Data:	2024
Resum:	Eosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic and localized forms of disease are typically treated with glucocorticoids. The approval of novel biologic therapies targeting the interleukin-5 pathway can help reduce the use of systemic glucocorticoids (SGC) in eosinophilic diseases and reduce the risk of SGC-related adverse effects (AEs). In this article, a panel of experts from different medical specialties reviewed current evidence on the use of SGC in two systemic eosinophilic diseases: Eosinophilic Granulomatosis with PolyAngiitis (EGPA) and HyperEosinophilic Syndrome (HES); and in two single-organ (respiratory) eosinophilic diseases: Chronic RhinoSinusitis with Nasal Polyps (CRSwNP) and Severe Asthma with Eosinophil Phenotype (SA-EP), and contrasted it with their experience in clinical practice. Using nominal group technique, they reached consensus on key aspects related to the dose and tapering of SGC as well as on the initiation of biologics as SGC-sparing agents. Early treatment with biologics could help prevent AEs associated with medium and long-term use of SGC.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adverse events ; Eosinophilic diseases ; Systemic glucocorticoids ; Biologics ; Tapering ; Treatment optimisation
Publicat a:	Frontiers in immunology, Vol. 14 (january 2024) , ISSN 1664-3224

DOI: 10.3389/fimmu.2023.1310211
PMID: 38250075

10 p, 531.5 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats